Skip Navigation
Print This Page
Share this page: More

Dr. Shawn Lupold

Shawn Lupold

Urological Oncology Radiation Oncology


Associate Professor of Urology
Associate Professor of Oncology

Secondary Appointments and affiliations:
Radiation Oncology and Molecular Radiation Sciences
Johns Hopkins Institute for NanoBioTechnology

Director, Molecular Biology Core for Small Animal Imaging Resources Program Johns Hopkins University School of Medicine


1988- 1992 B.S., Biology; Dept of Life Sciences, University of Maryland, College Park, MD 1993-1995 Pre-IRTA Fellow, Laboratory of Human Carcinogenesis, National Institutes of Health, National Cancer Institute, Bethesda, MD 1995-2001 Ph.D., Department of Pharmacology and Molecular Sciences, Biochemistry, Cellular, and Molecular Biology Graduate Program The Johns Hopkins University School of Medicine, Baltimore, MD 2001-2005 Post Doctoral Fellow, Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD


Post doctoral Fellow, Johns Hopkins University School of Medicine, Urology

Pre-doctoral Fellow, National Cancer Institute, National Institutes of Health

Research Summary

The Lupold laboratory focuses on prostate cancer biology with the goal of exploiting prostate tissue-specificity to develop new diagnostic, prognostic and therapeutic agents. Research projects stem from basic cancer biology, such as studying the role of microRNAs in the prostate cancer phenotype, to translational projects such as targeted siRNA and gene therapy. One area of interest is high diversity polymer libraries, including aptamers and peptides, which can be screened to identify high affinity cancer ligands. With this approach Dr. Lupold developed the first RNA aptamers targeted to a cancer cell surface antigen. He and others have applied these PSMA-targeting aptamers to deliver various therapeutic and imaging packages to prostate cancer cells and tumors.

Journal Citations

Ni X, Castanares M, Mukherjee A, and Lupold SE. Nucleic Acid Aptamer: clinical applications and promising new horizons. Cur Med Chem. 18(27), 4206-4214, 2011

Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Foss CA, Green G, Fox JJ, Lupold SE, Mease RC, Pomper MG. Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostate-Specific Membrane Antigen. Angew Chem Int Ed Engl. 2011 Sep 19;50(39):9167-70.

Sidana A, Wang M, Shabeer S, Carducci M, Chowdhury WH, Netto G, Lupold, SE, and Rodriguez R. Growth Inhibition of Prostate Cancer Xenografts upon Chronic Treatment with Valproic Acid (VPA) by Cell Cycle Arrest and Inhibition of Tumor Vasculature. J Pharmacol Exp Ther. In press.

Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z, Laiho M, DeWeese TL, and Lupold SE. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. Journal of Clinical Investigation. J Clin Invest. 2011 Jun 1;121(6):2383-90.

Sidana A, Wang M, Chowdhury W, Toubaji A, Shabbeer S, Netto G, Carducci MA, Lupold SE, and Rodriguez R. Does Valproic Acid induce Neuroendocrine Differentiation in Prostate Cancer? Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 607480, 10 pages, 2011.

Wu P, Kudrolli TA, Chowdhury WH, Minzhi ML, Rodriguez R, and Lupold SE. Adenovirus Targeting to Prostate-specific Membrane Antigen through Virus displayed Semi-random Peptide Library Screening. [Priority Report] Cancer Res. 2010 Dec 1;70(23):9549-53.

Ribas J and Lupold SE. The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle; 9(5), 923-9, 2010

Höti N, Chowdhury WH, Mustafa S, Ribas J, Castanares M, Johnson T, Liu M, Lupold SE, Rodriguez R. Armouring CRADs with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses. Cancer Gene Ther; 17(8):585-97, 2010
Liu C, Zhang Y, Liu, M, Zhou, H, Chowdhury WH, Lupold SE, DeWeese TL, Rodriguez R. Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer. Int J Radiat Biol; 86(3):220-9, 2010

Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi1 AH, Chowdhury WE, Kudrolli TA, Yegnasubramanian A, Luo J, Rodriguez T, Mendell JT, Lupold SE. miR-21: An androgen receptor regulated microRNA which promotes hormone dependent and independent prostate cancer growth. Cancer Research. [Priority Report] 69(18): 7165-9, 2009

Chen Y, Foss C, Byun Y, Nimmagadda S, Pullambhatla M, Fox J, Castanares M, Lupold SE, Babich J, Mease R, and Pomper M. Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer. J Med Chem. 25;51(24):7933-43, 2008

Banerjee S., Foss, C., Castanares M., Mease R., Byun Y., Fox J., Hilton J., Lupold SE., Kozikowski A., Pomper M. Radiology Synthesis and Evaluation of Technetium-99m- and Rhenium-labeled Inhibitors of the Prostate-specific Membrane Antigen (PSMA). J Med Chem. 14;51(15):4504-17, 2008

Lupold SE., Kudrolli T., Chowdhury W., Wu P, and Rodriguez R. "A Novel Method for Generating and Screening Peptides and Libraries Displayed on Adenovirus Fiber" Nucl. Acids Res. 35(20):e138, 1-10, 2007

Höti N, Li Y, Chen CL, Chowdhury WH, Johns DC, Xia Q, Kabula A, Hsieh JT , Berge M, Ketner G, Lupold SE and Rodriguez R "Androgen Receptor Attenuation of Ad5 Replication: Implications for the Development of Conditionally Replication Competent Adenoviruses" Mol Ther. 15(8):1495-503, 2007

Höti N, Chowdhury W, Hsieh JT, Lupold SE, and Rodriguez R "Valproic acid, a Histone Deacetylase Inhibitor, Is an Antagonist for Oncolytic Adenoviral Gene Therapy" Mol Ther. 14(6):768-78, 2006

Chen CL, Sung J, Cohen M, Chowdhury WH, Sachs MD, Li Y, Lakshmanan Y, Yung BYM, Lupold SE, Rodriguez R "Valproic Acid Inhibits Invasiveness in Bladder Cancer, but not in Prostate Cancer Cells" Pharmacol Exp Ther. 319(2):533-42, 2006

Lupold SE, Rodriguez R. "Adenoviral Vectors for Prostate Cancer Gene Therapy" Cancer Therapy, Vol 3, 267-284, 2005

Lupold SE, Rodriguez R. "Adenoviral Gene Therapy, Radiation, and Prostate Cancer" Reviews in Urology; Vol 7(4), 193-202. Fall 2005

Lupold SE., Rodriguez R. Disulfide-Constrained Peptides that Bind to the Extracellular Portion of the Prostate Specific Membrane Antigen. Mol Cancer Ther. 3(5):597-603, 2004

Hussain SP, Amstad P, He P, Robles A, Lupold S, Kaneko I, Ichimiya M, Sengupta S, Mechanic L, Okamura S, Hofseth LJ, Moake M, Nagashima M, Forrester KS, Harris CC. p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Research. 64(7):2350-6, 2004

Lupold SE., Hicke B.J., Lin Y., Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Research. 62(14):4029-33, 2002.

Wang XW., Vermeulen W., Coursen JD., Gibson JD., Lupold SE., Forrester K., Xu GW., Elmore L., Yeh H., Hoeijmakers JHJ., Harris CC., The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes and Development 10(10): 1219-1232, 1996

Forrester K., Ambs S., Lupold SE., Kapust RB., Spillare EA., Weinberg WC., Felleybosco E., Wang XW., Geller DA., Tzeng E., Billiar TR., Harris CC., 1996. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc. Natl. Acad. Sci. USA 93(6): 2442-2447, 1996

Forrester, K., Lupold SE., Ott VL., Chay CH., Band V., Wang XW., Harris CC., 1995. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependant. Oncogene 10(11): 2103-11, 1995


Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.